@entity164 2 @entity6 is characterized by the presence of both fasting and postprandial hyperglycaemia. Glycated haemoglobin is a marker of overall glycaemic exposure and integrates both fasting and postprandial hyperglycaemia. Epidemiologic and interventional studies in type 1 and type 2 @entity6 have demonstrated that chronic hyperglycaemia is associated with the appearance of chronic @entity2412 . More importantly, reducing glycated haemoglobin to achieve target goals prevents and avoid progression of complications, in particular microvascular outcomes. Although sustained chronic hyperglycaemia produces excessive protein glycation, acute fluctuations of @entity413 may activate oxidative stress and contribute to @entity409 , which may also participate in the development of @entity2412 . Therefore, reducing postprandial hyperglycaemia and @entity413 variability are now recognised as a priority in treatment of type 2 @entity6 . Therapeutic agents acting on postprandial @entity413 excursions are of particular interest to diminish @entity413 variability. Emerging therapeutic agents such as the @entity5445 agonists and the @entity5735 inhibitors are very attractive. Both increase insulin secretion and suppress glucagon release in response to meals, in a @entity413 -dependent manner. This review will focus on the increasing impact of postprandial hyperglycaemia and @entity13974 in developing @entity2412 and the role of @entity5735 inhibitors ( @entity12350 , @entity12349 , @entity15072 ) in reducing both defects presenting in @entity1 with type 2 @entity6 .

[Importance of daily glycemic variability in achieving glycemic targets in type 2 XXXX : role of @entity5735 inhibitors].

@entity1 :: ('9606', 'Species') :: ['people'] @entity5735 :: ('1803', 'Gene') :: ['DPP-4', 'dipeptidyl peptidase (DPP)-4'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity15072 :: ('MESH:C502994', 'Chemical') :: ['saxagliptin'] @entity12349 :: ('MESH:C502012', 'Chemical') :: ['vildagliptin'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin'] @entity164 :: ('MESH:D017827', 'Disease') :: ['Type'] @entity13974 :: ('MESH:C537362', 'Disease') :: ['glycaemic variability'] @entity2412 :: ('MESH:D048909', 'Disease') :: ['diabetes complications'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide 1']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
